TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07873827: A Phase 1/2, Open-label, Multicenter Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Efficacy of MEN2312 (KAT6 Inhibitor) in Participants With Hematological Malignancies

Sponsor: Stemline Therapeutics, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 115 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT07873827 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07873827 Rescue Dossier →